Effect of clopidogrel on high sensitive C-reactive protein and tumor necrosis factor-α in patients with acute coronary syndrome after percutaneous coronary intervention

Objective To observe the effect of clopidogrel on high sensitive C-reactive protein(hs-CRP) and tumor necrosis factor-α(TNF-α) in patients with acute coronary syndrome(ACS) after percutaneous coronary intervention(PCI). Methods 72 patients with ACS and PCI were randomly divided into two groups,patients in control group(35 cases) took 300 mg aspirin for the first time,then 100 mg aspirin every day,whereas patients in combination group(37 cases) took 300 mg aspirin and 300 mg clopidogrel for the first time,then 100 mg aspirin and 75 mg clopidogrel every day.2 groups were treated for 6 months.hs-CRP and TNF-αwere examined before taking medicine in all patients 10 and 30 days after taking medicine separately;prothrombin time(PT),activated partial thromboplastin time(APTT) and platelet count(PLT) were examined before taking medicine,30 days after taking medicine separately;the occurrence of cardiovascular events and adverse drug reactions within six months were observed.Results The hs-CRP,TNF-αof two groups on 10 days,30 days after treatment were decreased than before treatment(P0.05 or P0.01);the hs-CRP,TNF-αin the combination group on 10 days,30 days after treatment were decreased in combination group than that in the control group(P0.05 or P0.01); the incidence of cardiovascular events within 6 months in the combination group was significandy lower than that in the control group(2.7%vs 22.9%,P0.05);there was no significant difference of PT,APTT and PLT between two groups before treatment and 30 days after treatment(all P0.05 );the incidence of bleeding within 6 months was no significant difference between two groups(16.2%,8.6%,P0.05).Conclusion Clopidogrel can reduce the level of inflammation factors,reduce cardiovascular events.The anti-inflammatory effect of clopidogrel and aspirin were significantly stronger than that of single aspirin without increase the patient bleeding events.